Baird analyst Joel Beatty initiated coverage of Immutep with an Outperform rating and $7 price target.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IMMP:
- Immutep receives CHMP advice on development of eftilagimod alpha
- Immutep to present overall survival data from TACTI-002 Phase II trial
- Immutep reports Q4 cash receipts $16K vs. $30K last quarter
- Immutep announces first patient enrolled, dosed in EFTISARC-NEO trial
- First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue